Jagirdhar GSK, Perez JA, Perez AB, Surani S. Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease. World J Gastroenterol 2023; 29(36): 5211-5225 [PMID: 37901450 DOI: 10.3748/wjg.v29.i36.5211]
Corresponding Author of This Article
Salim Surani, FCCP, MD, MHSc, Academic Editor, Professor, Department of Medicine and Pharmacology, Texas A&M University, 400 Bizzell Street, College Station, TX 77413, United States. srsurani@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2023; 29(36): 5211-5225 Published online Sep 28, 2023. doi: 10.3748/wjg.v29.i36.5211
Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease
Gowthami Sai Kogilathota Jagirdhar, Jose Andres Perez, Andrea Belen Perez, Salim Surani
Gowthami Sai Kogilathota Jagirdhar, Department of Medicine, Saint Francis Health Science Center, Newark, NJ 07107, United States
Jose Andres Perez, Department of Medicine, Saint Francis Health Systems, Tulsa, OK 74133, United States
Andrea Belen Perez, Department of Research, Columbia University, New York, NY 10027, United States
Salim Surani, Department of Medicine and Pharmacology, Texas A&M University, College Station, TX 77413, United States
Author contributions: Jagirdhar GSK, Perez JA, and Perez AB performed the literature review, wrote the original manuscript; Surani S wrote the original manuscript, revised the paper, and approved the final version.
Conflict-of-interest statement: None of the co-authors declared any conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salim Surani, FCCP, MD, MHSc, Academic Editor, Professor, Department of Medicine and Pharmacology, Texas A&M University, 400 Bizzell Street, College Station, TX 77413, United States. srsurani@hotmail.com
Received: July 1, 2023 Peer-review started: July 1, 2023 First decision: July 10, 2023 Revised: July 31, 2023 Accepted: September 6, 2023 Article in press: September 6, 2023 Published online: September 28, 2023 Processing time: 80 Days and 16.1 Hours
Abstract
Inflammatory bowel disease (IBD) is a complex disease with variability in genetic, environmental, and lifestyle factors affecting disease presentation and course. Precision medicine has the potential to play a crucial role in managing IBD by tailoring treatment plans based on the heterogeneity of clinical and temporal variability of patients. Precision medicine is a population-based approach to managing IBD by integrating environmental, genomic, epigenomic, transcriptomic, proteomic, and metabolomic factors. It is a recent and rapidly developing medicine. The widespread adoption of precision medicine worldwide has the potential to result in the early detection of diseases, optimal utilization of healthcare resources, enhanced patient outcomes, and, ultimately, improved quality of life for individuals with IBD. Though precision medicine is promising in terms of better quality of patient care, inadequacies exist in the ongoing research. There is discordance in study conduct, and data collection, utilization, interpretation, and analysis. This review aims to describe the current literature on precision medicine, its multiomics approach, and future directions for its application in IBD.
Core Tip: Precision medicine holds significant promise in managing inflammatory bowel disease (IBD) by aiming to customize treatments based on the unique biological characteristics of patients. Despite advancements in biological and small-molecule therapies offering new therapeutic options for IBD; however, the is a large gap in understanding the clinical course of IBD, the durability of treatment response, and enhancing available and new therapeutic options. Integrating multiomics into patient care can help in early diagnosis, predict disease course, deliver targeted treatments based on unique patient profiles, and evaluate prognosis.
